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ABSTRACT 
 
Cardiovascular diseases are the leading cause of death in the United States. 
Atherosclerosis, a cardiovascular disease, can lead to stroke and heart failure, affecting 50% of 
the U.S. population over the age of 65
1
. One of the first steps in the progression of 
atherosclerosis is increased endothelium permeability, ultimately resulting in the accumulation of 
lipids and formation of plaque. It has been shown that increased substrate stiffness, mimicking 
the stiffening that occurs naturally with age, results in increased cell contractility, cell-cell 
junction width, and endothelium permeability via Rho mediated contractility 
2
. To date 
therapeutics to reverse increased vascular stiffness, and in turn prevent endothelial cell 
dysfunction leading to increased endothelium permeability, have been limited and unsuccessful. 
Previous findings suggest that statins may be beneficial beyond lowering cholesterol levels by 
having a positive effect on endothelium integrity through the inhibition of RhoA in the 
actomyosin contractility pathway 
3–5
. As increased stiffness leads to increased permeability via 
Rho mediated contractility 
2
 and statins have been shown to decrease RhoA activity, this 
investigation examined the effect of simvastatin (Zocor®), a common statin, on endothelial cell 
morphology, cell traction forces, cell-cell junction widths, and endothelium permeability for 
endothelial cells seeded on 2.5, 5, and 10 kPa polyacrylamide substrates, mimicking the stiffness 
of healthy and aged vessels respectively.  
Our data show that simvastatin results in an elongated cell morphology, reduced 
endothelial cell contractility, enhanced cell-cell junction integrity, and decreased substrate-
stiffness-dependent and thrombin-dependent increased endothelium permeability on 
physiologically relevant substrate stiffnesses. Our data suggest that simvastatin may be beneficial 
  
in preventing atherosclerosis beyond its traditional lipid lowering effects by decreasing 
monolayer permeability due to vascular stiffening that naturally occurs with aging. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Atherosclerosis 
Cardiovascular diseases are the leading cause of death in the United States, claiming 
approximately 2,150 lives per day, according to the American Heart Association 
1
. 
Atherosclerosis, which can lead to stroke and heart failure, is a progressive disease that begins 
with endothelial cell dysfunction followed by the accumulation of low-density lipoprotein (LDL) 
particles in the intima. This results in the formation of sub-endothelial accumulations of LDL 
and cholesterol-engorged macrophages, also known as foam cells 
6,7
. Over time, as white blood 
cells, LDL, and other fatty materials permeate the endothelial cell layer an atherosclerotic plaque 
begins to form 
8
. Eventually, as this plaque continues to grow it will begin to occlude the vessel 
and restrict blood flow 
9
. These plaques can become unstable and rupture, leading to the 
formation of thrombi causing complications such as a myocardial infarction or stroke 
9,10
.  
Atherosclerosis affects 50% of the population over the age of 65 
1
. This suggests a 
connection between atherosclerosis and aging; however, the exact mechanism by which aging 
leads to the progression of atherosclerosis remains unclear. Notably, during both aging and 
atherosclerosis, the blood vessel stiffens due to increased elastin fragmentation, collagen 
deposition, and collagen cross-linking 
2,11
. Measurements of vessel stiffness, quantified through 
pulse wave velocities, are used clinically to determine a patient’s risk of developing 
cardiovascular diseases 
12,13
. While the connection between macro-scale artery stiffness and 
cardiovascular diseases is well characterized, the relationship between increased vessel stiffness 
and endothelial cell function is less clear. Recent work has shown, using in vitro and ex vivo 
2 
 
models of vessel stiffness and aging, that increasing substrate stiffness alone can promote 
endothelial monolayer disruption including increased endothelium permeability, the first step in 
the progression of atherosclerosis 
2
. In addition, inhibition of Rho-dependent cell contractility 
restores monolayer integrity, reversing the increased endothelium permeability, destabilized cell-
cell junctions, and increased cell contractility due to increased substrate stiffness. This work 
suggests targeting the Rho-dependent cell contractility pathway to prevent the cellular response 
to increasing extracellular matrix stiffness as a means to prevent the progression of 
atherosclerosis.  
 
1.2 Importance of Matrix Mechanics   
Mechanotransduction is the process by which cells convert forces to biochemical signals. When 
a mechanical force is applied to a cell, it activates numerous signaling pathways that mediate the 
cell’s response 14–16. Matrix mechanics have been shown to play a key role in endothelial cell 
behavior, and as such it is an important factor to account for when studying vascular diseases, 
such as atherosclerosis 
2,17,18
. The vascular endothelium maintains its integrity by balancing cell-
cell and cell-matrix forces 
19
. Previous work shows that endothelial cell traction stresses are 
dependent on substrate stiffness, with increasing substrate stiffness leading to increased traction 
stress 
18,20
. Traction forces have been shown to originate from actomyosin interactions within 
cells 
2,18,21
. Myosin activity can be regulated through a number of mechanisms, one of which 
includes the phosphorylation of myosin light chain (MLC) by either myosin light chain kinase 
(MLCK) or Rho associated kinase (ROCK) 
22,23
.  
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 As previously mentioned, it has been shown that vessel stiffness increases with both age 
and the progression of atherosclerosis. The exact stiffness of the intima of human arteries is not 
well characterized as it is difficult to obtain samples; as such, Peloquin et al. and Huynh et al. 
have have characterized the stiffness of bovine and mouse arteries respectively. The stiffness of 
18 to 30 month old bovine carotid intima was reported to be 2.7 ± 0.6 kPa 
24
. As the structure of 
bovine arteries is analogous to that of human arteries, this value is a good estimate of the 
stiffness of a young or healthy adult’s artery.  
Mechanotransduction has been shown to be regulated by the crosstalk between cadherins 
and integrins during disease progression 
25,26
. A key cadherin in endothelial cells is vascular 
endothelial (VE) cadherin. VE-cadherin is essential for limiting endothelium permeability and 
maintaining vascular integrity as it is a major component of endothelial adherens junctions 
27
. 
Adherens junctions are zipper-like structures that form along cell borders, linking one cell to 
another 
28
. VE-cadherin interacts with the actin cytoskeleton through scaffolding proteins called 
catenins. This interaction suggests that actomyosin contraction regulates these cell-cell adhesions 
28–30
. In addition, when VE-cadherin is phosphorylated, adherens junctions separate due to VE-
cadherin degradation and internalization resulting in increased endothelium permeability 
31
.  
In addition to matrix mechanics, soluble mediators, such as thrombin, have been shown 
to play a role in regulating endothelial cell monolayer integrity 
20
. Upon thrombin stimulation, it 
has been shown that endothelial monolayers become more permeable through the activation of 
RhoA and subsequent phosphorylation of MLC 
32,33
. Recently, thrombin has been shown to be an 
important contributor to endothelial cell dysfunction in atherosclerosis. Borissoff et al. published 
in vivo results showing that deletion of a thrombin inhibitor promotes an accelerated atherogenic 
state, while the administration of a thrombin inhibitor ameliorated atherosclerotic plaque 
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progression 
34
. Through this work thrombin has been shown to play an important role in both the 
progression of atherosclerosis and increased endothelium permeability. 
 
1.3 Statins to Reduce Endothelial Dysfunction 
1.3.1 Isoprenoid Biosynthesis Pathway 
The most common treatment for hypercholesterolemia today is a class of drugs called 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, more commonly 
known as statins. This class of drugs lowers blood cholesterol levels by inhibiting HMG-CoA 
reductase, the enzyme that converts HMG-CoA to mevalonate, the rate-limiting step in the 
isoprenoid biosynthesis pathway (Figure 1), the end product of which is cholesterol 
35
. In 
addition to lowing cholesterol levels, statins have been found to reduce the risk of stroke and 
myocardial infarction beyond what can be explained by the drug’s cholesterol lowering abilities 
3–5,36
. It is now evident that inhibition of the isoprenoid biosynthesis pathway leads not only to a 
decrease in cholesterol levels, but also blocks the synthesis of farnesylpyrophosphate (Farnesyl-
PP) and geranylgeranylpyrophosphate (Geranylgeranyl-PP) which serve as important lipid 
attachments for the posttranslational modification of small GTP-binding proteins, such as those 
belonging to the Rho family guanosine triphosphatases (GTPases) 
37
. Farnesylastion and 
geranylgeranylation have been shown to be important for proper function and intracellular 
localization of Rho GTPases, such as RhoA, Rac1, and Cdc42 
37
. Without proper 
posttranslational modification, these small GTPases are not able to properly function, which has 
been suggested to lead to the pleiotropic effects of statins on the vascular wall.  
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Figure 1: Pathway representing the connection between simvastatin and the isoprenoid 
biosynthesis pathway. This image was adapted from Rikitake et al. 
37
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1.3.2 Actomyosin Contractility Pathway 
The primary role of the Rho GTPases is to regulate the assembly and organization of the actin 
cytoskeleton 
38
, which has implications in the generation of contractile forces 
39
 and the 
maintenance of barrier integrity 
40
. GTPases cycle between an inactive GDP-bound state and an 
active GTP-bound state, in doing so they act as molecular switches in a variety of signaling 
pathways 
40
. Three classes of regulatory proteins control the activation state of Rho GTPases: 1) 
GTPase-activating proteins (GAPs) hydrolyzes GTP to GDP, inactivating the protein, 2) guanine 
nucleotide exchange factors (GEFs) promote the exchange of GDP for GTP, activating the 
protein, and 3) guanine nucleotide dissociation inhibitors (GDIs) which bind to and stabilize the 
prenylated GDP-bound Rho GTPases 
41
 (Figure 2).  
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Figure 2: Biochemical pathway showing the interaction between simvastatin, the mevalonate 
pathway, and the actomyosin contractility pathway which ultimately leads to a change in 
endothelial contractility and permeability resulting in the progression of atheroscelerosis. 
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RhoA, Rac1, and Cdc42 are the best characterized Rho GTPases in terms of their role in 
the regulation of endothelial barrier integrity. RhoA has been shown to primarily have 
destabilizing effects on endothelial barrier integrity, while Rac1 and Cdc42 tend to stabilize 
junctional complexes 
40,42
. RhoA acts to destabilize endothelial barrier integrity through the 
actomyosin contractility pathway by acting on its effector, Rho-associated kinase (ROCK) 
22,43
. 
First, RhoA-GDP binds to the cellular membrane via its isprenoid group. RhoA-GDP can then be 
phosphorylated (activated) by a GEF converting it to membrane bound RhoA-GTP, which is the 
primary form that RhoA must be in to act on its effector ROCK. Once activated, ROCK can 
either directly or indirectly lead to increased levels of phosphorylated MLC 
22,38,44
. ROCK 
inactivates myosin light chain phosphatase (MLCP), inhibiting the dephosphorylation of myosin 
light chain (MLC) indirectly leading to increased levels of phosphorylated MLC 
22,44
 (Figure 2). 
It has been suggested that as the ratio of phosphorylated MLC to MLC increases, endothelial 
cells become more contractile, in turn destabilizing cellular junctions 
22,45
 leading to increased 
endothelium permeability. It is through this pathway that statins are thought to modulate cellular 
contractility and ultimately decrease endothelium permeability.  
 
1.3.3 Simvastatin 
Statins, classically prescribed to lower serum cholesterol levels, work by inhibiting the hepatic 
enzyme HMG-CoA reductase, entering hepatocytes via the organic anion transporter. It is 
currently thought that statins enter nonhepatic cells via passive diffusion as specific transporters 
have yet to be identified 
46
. There are a number of different statins currently on the market, each 
with varying levels of potency for inhibiting hepatic HMG-CoA reductase 
3,36
. In addition, these 
statins differ in their tissue permeability and metabolism resulting in different potencies for 
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extrahepatic HMG-CoA reductase inhibition. The statins considered most likely to enter 
endothelial cells via passive diffusion are the lipophilic statins, such as simvastatin 
46
. 
Simvastatin, originally marketed exclusively by Merck under the brand name Zocor®, was the 
number two best-selling pharmaceutical in 2002, 2003, and 2004, selling more than $3 billion 
each year 
47
. Prior to losing U.S. patent protection, in 2006, Zocor was the second largest selling 
statin in the world behind Lipitor whose U.S. patent recently expired in 2011.  
 
1.3.4 Previous Studies Conducted with Endothelial Cells 
Thus far groups have primarily investigated the effect of simvastatin on endothelial cell 
monolayer integrity without accounting for biomechanical stimuli such as matrix stiffness 
48–51
. 
These studies were primarily conducted using Transwell plates which serve as a nice model for 
permeability; however, Transwell plates have very high stiffnesses when compared to 
physiological stiffnesses.  Using this model, it has been shown that pre-incubation with 
simvastatin reduces thrombin-induced endothelial barrier dysfunction 
50–52
. In addition, 
simvastatin has been shown to downregulate key proteins in the actomyosin contractility 
pathway such as RhoA and phosphorylated MLC 
50,51
.   
 
1.4 Scope of this Project 
The primary goal of the work presented in this thesis was to investigate the potential for 
simvastatin to modulate increased endothelium permeability on substrates with physiologically 
relevant stiffnesses. The motivation for this research comes primarily from three areas of work.  
10 
 
First, numerous groups have shown that in addition to inhibiting the synthesis of cholesterol, 
simvastatin inhibits the activity of proteins in the actomyosin contractility pathway such as Rho 
3,36,53–55
. Second, it has been demonstrated that increased substrate stiffness leads to increased 
cell contractility via the actomyosin contractility pathway ultimately resulting in increased 
endothelium permeability 
2
. Third, a number of groups have shown that simvastatin treatment 
reduces endothelium permeability and prevents increased permeability induced by thrombin on 
tissue culture plastic 
32,50,51,56
. As this work was conducted on tissue culture plastic,  with 
stiffness ~10
6
 kPa 
57
, it is unclear as to how these results will translate to substrates with 
physiologically relevant stiffnesses. Given that increased substrate stiffness leads to increased 
endothelial cell contractility and endothelium permeability via Rho mediated contractility 
2
 and 
statins have been shown to decrease RhoA activity, my goal was to examine the effect of 
simvastatin on endothelial cell morphology, cell contractility, cell-cell junction widths, and 
endothelium permeability for endothelial cells on 2.5, 5, and 10 kPa PA substrates, mimicking 
the stiffness of healthy and aged vessels respectively (Figure 3).  
11 
 
 
 
Figure 3: Pathway representing the connection between aging, simvastatin, and the progression 
of atherosclerosis. Aging leads to increased matrix stiffness which activates the actomyosin 
contractility pathway. Simvastatin inhibits a key protein, RhoA, in the actomyosin contractility 
pathway ultimately leading to a decrease in contractility and permeability preventing the 
progression of atherosclerosis.  
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Overview 
An in vitro atherosclerosis model that accounts for blood vessel stiffening that occurs 
with aging was used for this work. This model employs polyacrylamide gels of 2.5, 5, and 10 
kPa seeded with bovine aortic endothelial cells (Figure 4). Peloquin et al. and Huynh et al. 
measured the stiffness of bovine and mouse arteries respectively. Bovine and mouse arteries 
were selected given their similarities to human arteries and availability at a variety of ages. The 
stiffness of 18 to 30 month old bovine carotid intima was reported to be 2.7 ± 0.6 kPa 
24
. This is 
a good estimate of the stiffness of a young or healthy human adult artery because the structure of 
bovine arteries is analogous to that of human arteries. To get an idea of how vessel stiffness 
changes with age, Huynh et al. characterized the intimal stiffness of young (10 to 11 weeks) and 
old (21 to 25 months) mice. The measured modulus for old mice was found to be higher than the 
value for young mice confirming that there is a relative increase in blood vessel stiffness with 
increasing age 
2
. In our in vitro model, 2.5 kPa polyacrylamide gels were selected to represent 
young vessels and two higher stiffness polyacrylamide gels, 5 and 10 kPa, were selected to 
represent aged vessels.   
 This in vitro atherosclerosis model was employed look at the effect of various treatment 
conditions on a series of readouts including, LIVE/DEAD assay, shape factor, cell traction force, 
cell-cell junction, endothelium permeability, and Rho activity (Figure 5). The treatment 
conditions included no simvastatin, simvastatin, thrombin, and simvastatin followed by 
thrombin. The treatment conditions were selected based on the literature and then optimized for 
our in vitro model. 
13 
 
 
 
 
 
 
 
 
 
 
Figure 4: In vitro atherosclerosis model. Polyacrylamide (PA) gel on glass coverslip seeded with 
bovine aortic endothelial cells (BAECs). 
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Figure 5: Schematic of research plan. Blue represents known atheroprotective conditions, red 
represents known atheroprone conditions, and purple represents conditions with no known 
effects on the progression of atherosclerosis.  
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2.2 Cell Culture 
All experiments were conducted using bovine aortic endothelial cells (BAECs) purchased from 
VEC Technologies (Rensselaer, NY). Cells were maintained at 37ºC and 5% CO2 in Medium 
199 (Invitrogen, Carlsbad, CA) with 10% Fetal Clone III (HyClone, Logan, UT), 1% MEM 
amino acids (Invitrogen), 1% MEM vitamins (Medtech, Manassas, VA), and 1% penicillin-
streptomycin (Invitrogen), this will be referred to as complete M199. BAECs were used from 
passages 7-10.  
 
2.3 Preparation of Glass Coverslips 
PA substrates are prepared by allowing polyacrylamide solutions to polymerize between two 
glass coverslips. One of the coverslips must be activated to allow the polymerized PA to adhere 
for the duration of the experiment. Glass coverslips (No. 2, 22 x 22mm, No. 1, 43 x 50mm, and 
No. 1, 48 x 65mm, VWR, West Chester, PA) were plasma cleaned for 2 minutes.  Plasma 
cleaned samples were placed in a 1% PEI (polyethylenimine) solution in Milli-Q water for 10 
minutes at room temperature. Samples were rinsed with Milli-Q water and inverted onto a 0.1% 
glutaraldehyde solution in Milli-Q water for 30 minutes at room temperature. Samples were 
thoroughly rinsed 3 times in Milli-Q water for 5 minutes each. Samples were allowed to 
completely dry prior to using. Activated coverslips were used within one month of activating.  
The second coverslip must be removed after polymerization of the substrate. Glass coverslips 
(18mm diameter, 48 x 65mm, VWR) were coated with Rain-X and allowed to dry for 
approximately 5 minutes. Excess Rain-X was removed from the coverslip using a Kimwipe. 
Particulates were removed by gently spraying the coverslip with a stream of air. 
16 
 
2.4 Polyacrylamide substrate synthesis  
PA gels were synthesized as previously described (Califano and Reinhart-King, 2008). 2.5, 5, 
and 10 kPa gels were polymerized onto activated glass coverslips. The stiffness of the gel is 
determined by the ratio of acrylamide to bis-acrylamide. For the 2.5, 5, and 10 kPa PA gels used 
throughout the experiments described the ratios (% acrylamide: % bis-acrylamide) were, 5:0.1, 
7.5:0.175, 7.5:0.35, respectively. After polymerization, the gels were functionalized with 0.1 
mg/ml rat tail type I collagen (BD Biosciences, San Jose, CA).   
 
2.5 Drug Treatments 
Simvastatin (Sigma-Aldrich) prodrug was activated prior to use as previously described 
58–60
. 
Briefly, 5 mg of simvastatin prodrug was dissolved in 125 µl of 200 proof ethanol. This solution 
was incubated with 187.5 µl 0.1 N NaOH for 2 hours at 50ºC. Then, 600 µl MilliQ water was 
added and the pH was brought to 7.0 using 0.1 N HCl. The solution was diluted to yield a final 
concentration of 10 mM and was stored at 4ºC. For treatments, the 10 mM stock was diluted to 
concentration of 1, 5, 50, and 200µM in M199 or L15 (for permeability study only) media. 
Bovine thrombin (Calbiochem, San Diego, CA) was used at a concentration of 4 U/ml. 40-kDa 
FITC conjugated dextran (Sigma-Aldrich) was used at a concentration of 10 µM in L15 for 
permeability studies.  
 
17 
 
2.6 LIVE/DEAD® Cell Viability Assay 
BAECs were seeded on 2.5 and 10 kPa PA gels at a density of 15,000 cells/cm
2
 and allowed to 
grow to confluence. Two days post confluence cells were treated with 0, 0.1, 0.5, 1, 5, or 10 µM 
simvastatin or an ethanol control. The ethanol control contained an equivalent amount of ethanol 
as the 1 µM simvastatin treatment condition. This control was included to ensure that the ethanol 
used to dissolve the simvastatin prodrug was not toxic to the cells. Following treatment, cell 
viability was assessed using a LIVE/DEAD® cell viability kit (Invitrogen) according to the 
manufacturer’s protocol. Ethidium homodimer-1 was used at a concentration of 4mM, and 
calcein was used at a concentration of 2mM. After a 30 minute incubation with the dye solution 
the solution was removed and replaced with complete M199. Samples were imaged within one 
hour to ensure no additional cell death. Fluorescent images were acquired on a Zeiss Axio 
Observer.Z1m microscope equipped with a Hamamatsu ORCA-ER camera using a 10x 
objective.  
 
2.7 In vitro quantification of cell shape factor  
BAECs were plated in a 24-well plate at a density of 2,500 cells/cm
2
 and allowed to reach 50% 
confluence prior to treatment with simvastatin. Simvastatin was diluted with M199 complete 
media to concentrations of 1 and 5µM. Cells were treated for 6, 16, 24, 36, and 48 hours. The 
media was then removed and cells were fixed with 3.7% formaldehyde (VWR International, 
West Chester, PA) and permeabilized with 1% Triton (VWR). Cells were incubated with a 1:200 
dilution Alexa Fluor® 488 Phallodin (Life Technologies). Fluorescent images were captured on 
a Zeiss Axio Observer Z1m microscope equipped with a Hamamatsu ORCA-ER camera using a 
18 
 
20x objective. All cells in the field of view were hand traced in ImageJ. Data on the cell’s area, 
perimeter, centroid, major and minor axis, and angle were collected and used to calculate each 
cell’s shape factor 61. Shape factor can take on values between zero and one, with zero 
representing a line and 1 representing a circle.   
 
              
        
          
         
 
2.8 Traction force microscopy 
BAECs were seeded at a density of 300 cells/cm
2
, to ensure the presence of isolated cells, on 2.5, 
5, and 10 kPa PA gels embedded with 0.5 µm diameter fluorescent beads (Invitrogen). Cells 
were allowed to adhere for 16 hours after which the media was removed and replaced with 
complete M199 containing 1µM simvastatin for the treatment condition and complete M199 
without simvastatin for the untreated condition. After 24 hours, phase contrast images of single 
cells were taken immediately followed by fluorescent images of the bead field beneath the cell 
(Figure 6). A second fluorescent image of the bead field in an unstressed state was taken after the 
cells were removed with 0.05% trypsin/EDTA (Invitrogen). Using the LIBTRC analysis library 
developed by M. Dembo (Dept. of Biomedical Engineering, Boston University), the bead 
displacements within the gel were calculated and used in combination with the gel’s material 
properties to calculate the most likely cellular traction vectors, T, and the total magnitudes of 
force 
62
. The overall force, | F |, exerted by the cell is the integral of the traction vector 
magnitudes, T, over the cell area, represented by the equation below, where        
19 
 
[               ] is the continuous field of traction vectors defined at any spatial position 
      over the cell area 63.  
 
| |  ∬√(                 )         
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Figure 6: (A) Phase image of BAEC. (B) Zoomed in overlay of unstressed (green) and stressed 
(red) bead fields. (C) Image of force vectors calculated from bead trace. (C) Image of stress 
magnitudes, displaying magnitude of cellular force in Pascals. 
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2.9 In vitro quantification of VE-cadherin junction gap width  
BAECs were seeded on 2.5, 5, and 10 kPa PA gels at a density of 15,000 cells/cm
2 
and allowed 
to grow to confluence. Two days post confluence cells were treated with 1 µM simvastatin for 24 
hours. Then cells were fixed and permeabilized with 3.7% formaldehyde (VWR) and 1% Triton 
(VWR), respectively. Cells were incubated with a 1:50 dilution of goat polyclonal VE-cadherin 
primary antibody (Santa Cruz Bio-technology, Santa Cruz, CA) and a 1:200 dilution of Alexa 
Fluor® 568 donkey anti-goat secondary antibody (Invitrogen). Fluorescent images were acquired 
on a Zeiss Axio Observer.Z1m microscope equipped with a Hamamatsu ORCA-ER camera 
using a 20x objective.  
VE-cadherin junction width was quantified using ImageJ and a custom-written MATLAB 
algorithm previous described 
2
. Briefly, a line was drawn perpendicular to the junction in ImageJ 
using the fluorescent VE-cadherin images giving an intensity profile for each junction. The 
intensity profile was fit with a two-Gaussian curve in MATLAB. Junction widths were defined 
as the width of the two-Gaussian fit.  
 
2.10 In vitro measurement of endothelium permeability 
BAECs were seeded onto PA gels with a diameter of 18mm at a density of 15,000 cells/cm
2
 and 
allowed to grow to confluence. At two days post-confluence, untreated cells were given 
Leibovitz’s L15 media containing 10% FetalClone III (HyClone) and 1% penicillin-streptomycin 
(Invitrogen) and treated cells were given this media with 10, 20, or 50 µM simvastatin for the 
thrombin permeability experiment or 200 µM simvastatin for the no thrombin permeability 
experiements and maintained at 37ºC. After 6 hours, the permeability was evaluated by adding a 
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10 µM solution of 40 kDa FITC-dextran to the cells for 10 minutes. Confocal z-slice images 
were then acquired on a Leica TCS SP2 system equipped with a 40x dipping lens. Three images 
were taken at three different spots on each gel. For the thrombin permeability experiment, 4 
U/ml of thrombin was added to the 10 µM solution of 40 kDa FITC-dextran for 10 minutes and 
imaged in the same manner as previously described. 
Endothelium permeability was quantified by measuring the fluorescent intensity above 
and below the cell layer using ImageJ as previously described 
2
. Briefly, the pixel intensity inside 
a 50 by 400 pixel box above the cell layer was recorded. Next, the pixel intensity within the gel 
was determined and recorded by drawing a 400 wide box encompassing the entire height of the 
gel. This value represents the amount of FITC-dextran that permeated the cell monolayer into the 
gel over 10 minutes. Average permeability was calculated by dividing the average pixel intensity 
within the gel by the average pixel intensity above the gel. Since the permeability of the gels is 
dependent on their stiffness, the average permeabilities were divided by the average permeability 
calculated for gels without cells giving the permeability value that were reported. 
 
2.11 Measurement of RhoA Activity 
BAECs were seeded at a density of 15,000 cells/cm
2
 on 48 x 65 mm PA gels with Young moduli 
of 2.5, 5, and 10 kPa. Cells were grown to confluence and treated with 1 µM simvastatin for 24 
hours at two days post confluence. In this case, larger PA gels were used to ensure that there 
were enough cells for the assay. Immediately following treatment, cells were lysed at 4ºC and 
stored at -80ºC until the RhoA assay was run. BAEC intercellular RhoA activity was measured 
using a RhoA G-LISA kit (Cytoskeleton, Denver, CO) according to the manufacturer’s protocol. 
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RhoA activity was normalized to total DNA measured using the Quant-iT™ PicoGreen® Assay 
(Invitrogen).  
 
2.12 Statistical Analysis  
Statistical analysis was conducted in JMP v. 10. All data is mean ± SEM (standard error of 
means). For the cell viability and shape factor analyses, a Tukey’s Honestly Significant 
Difference (HSD) test was performed. For all other experiments, a standard least square 
regression with a post hoc Tukey’s HSD was performed.  
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CHAPTER 3 
RESULTS 
 
3.1 BAEC Viability with Simvastatin Treatment 
To ensure that simvastatin treatment was not significantly affecting endothelial cell viability, cell 
death was quantified using a LIVE/DEAD assay. Cell viability was assessed for endothelial cell 
monolayers treated with 0, 0.1, 0.5, 1, 5, and 10 µM simvastatin for 24 hours on 10 kPa PA gels 
(Figure 7A). As ethanol is required to dissolve the simvastatin prodrug prior to activation, an 
ethanol control sample was also included. For the ethanol control, an equivalent amount of 
ethanol as in the 1 µM simvastatin condition was used to ensure that the ethanol was not having 
a negative effect on cell viability. Percent cell death was not statistically different than untreated 
values for the 0.1, 0.5, and 1 µM simvastatin treatments (Figure 7B). Additionally, the ethanol 
control caused no significant decrease in cell viability compared to the untreated and 1 µM 
simvastatin treated conditions. This suggests that the ethanol used to dissolve the simvastatin 
prodrug had no negative effect on cell viability. Percent cell death was found to increase 
compared to the no drug control for 5 and 10 µM simvastatin treatments, increasing by 1.7 and 
2.4% respectively. However, the percent cell death remained below 5% for both the 5 and 10 µM 
simvastatin treatment conditions. Similar results were found for cells seeded on tissue culture 
plastic and 2.5 kPa PA gels.  
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Figure 7: Quantification of cell viability. (A) Fluorescent images of endothelial cell monolayers 
on 10 kPa PA gels after a 24 hour 0, 1, or 5 µM simvastatin treatment, stained with green-
fluorescent calcein-M to indicate intracellular esterase activity and red-fluorescent ethidium 
homodimer-1 to indicate loss of plasma membrane integrity. Scale bar, 100 µm. (B) 
Quantification of LIVE/DEAD assay results for cells seeded on 10 kPa PA gels and treated with 
various simvastatin concentrations for 24 hours. Data collected in collaboration with Kate Gefell. 
Data ± SEM. N = 1 with 8-10 images and 2-3 independent gels per condition. *P < 0.005 
(Tukey’s HSD test).
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 3.2 Simvastatin Treatment Affects BAEC Morphology  
Cell morphology has been shown to be associated with changes in actomyosin contractility, with 
inhibition of RhoA decreasing cellular contractility resulting in cells with a more elongated 
morphology 
64
. A number of groups have shown that simvastatin treatment decreases RhoA 
activity 
32,66,67
. Likewise, previous research has shown that endothelial cells treated with 
simvastatin have a more elongated morphology when compared to untreated cells 
52
. As such, we 
sought to investigate the effect of simvastatin concentration and treatment time on cell 
morphology. Cell morphology was quantified by shape factor which distinguishes between 
elongated and round cells on a scale from 0 to 1, respectively (Figure 8A). Sub-confluent BAECs 
were treated with various concentrations of simvastatin (0, 1, and 5 µM) for up to 48 hours 
(Figure 8B). During this time period, the shape factor for untreated BAECs increased from 0.33 
± 0.009 to 0.53 ± 0.009. In contrast, the shape factor for cells treated with 1 µM simvastatin 
remained fairly consistent starting at 0.31 ± 0.008 and increasing slightly to 0.36 ± 0.007. After 6 
hours of treatment with 5 µM simvastatin cells had a shape factor that was significantly lower 
than control and 1 µM simvastatin treated cells. For cells treated with 5 µM simvastatin, the 
shape factor was 0.29 ± 0.007 at 6 hours and decreased slightly to 0.24 ± 0.01 by 48 hours. As 
shown in Figure 8, the shape factor was found to be significantly lower compared to the 
untreated condition at all treatment times and concentrations except 1 µM for 6 and 16 hours. 
Our results show that simvastatin-treated endothelial cells were slightly elongated when 
compared with untreated cells. This result is consistent with previous work published on 
endothelial cell morphology in monolayers in response to simvastatin treatment 
52
. Changes in 
cell morphology may have consequences for cell contractility and permeability 
68
 and suggests 
that simvastatin may be decreasing RhoA activity 
21,64,65
. 
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Figure 8: Shape factor as a function of simvastatin treatment time and concentration.               
(A) Fluorescent images of BAECs stained for actin after 16 and 48 hours of treatment with 0, 1, 
or 5µM simvastatin. Scale bar represents 40 µm.  (B) Quantification of shape factor for BAECs 
treated with 0, 1, and 5 µM simvastatin for 6, 16, 24, 36, and 48 hours. Error bars represent 
SEM. N=1 with 170 to 230 cells per condition. Simvastatin treatments were compared to the 
untreated control for each time point using Tukey’s HSD test. * p<0.01. 
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 3.3 Simvastatin Treatment Decreases Substrate Stiffness-Dependent Increased 
Contractility 
We previously showed that endothelial cells treated with simvastatin adapt an elongated cell 
morphology. To determine if this change in cell morphology translated to a change in cell 
contractility, we examined cell contractility using traction force microscopy. Additionally, it has 
been shown that endothelial cell contractility increases with increasing substrate stiffness and 
that this increase can be ameliorated with the addition of the ROCK inhibitor, Y-27632 
2
. From 
previous work, we hypothesized that simvastatin may inhibit substrate stiffness dependent 
increased contractility through Rho, as it has been shown to inhibit Rho activity 
50
. To 
investigate the effect of substrate stiffness and simvastatin treatment on endothelial cell 
contractility, we quantified the forces exerted by the cells on their substrate using traction force 
microscopy (TFM) (Figure 9). A treatment of 1 µM simvastatin for 24 hours was selected for 
this experiment based on our cell viability results (Figure 7) and previously published data 
52
. 
Our TFM results indicate that cellular force significantly (p < 0.01) increases for untreated cells 
seeded on 2.5, 5, and 10 kPa gels. These results support previously work showing that cellular 
force increases as a function of matrix stiffness 
2
. With the addition of 1 µM simvastatin for 24 
hours, we noted a decreasing trend for all stiffnesses tested when compared with the 
corresponding untreated condition. Most notably, there was a significant (p < 0.01) decrease in 
cell force upon simvastatin treatment on 10 kPa gels. These results demonstrate that simvastatin 
is able to reverse substrate stiffness-dependent increased cell contractility, with a significant 
decrease on stiffer (10 kPa) gels.   
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Figure 9: Quantification of cell contractility through TFM measurements. Effect of a 24 hour 1 
µM simvastatin treatment and substrate stiffness on cellular traction force. Data are means ± 
SEM. *P < 0.01 (Standard Least Square Regression with post hoc Tukey’s HSD). N=3 with 50 
to 80 cells per condition.  
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3.4 Simvastatin Treatment Decreases Substrate Stiffness-Dependent Increased Cell-cell 
Junction Width 
Cellular contractility and junction width play a key role in regulating endothelium permeability 
42
. It has been previously shown that increased cellular contractility leads to destabilized cell-cell 
junctions causing increased endothelium permeability 
2
. Our data show that simvastatin reduces 
cell contractility on 10 kPa PA gels, as such; we sought to investigate the effect of simvastatin on 
cell-cell junction width to determine whether the decrease in cell contractility translated to a 
decrease in cell-cell junction width. Increased cellular contractility has been shown to increase 
cell-cell junction width 
2
. To investigate the effect of simvastatin on cell-cell junction width, 
fluorescent images of VE-cadherin junctions were analyzed to quantify the junction width 
(Figure 10A). A treatment of 1 µM simvastatin for 24 hours was used for this experiment 
because it significantly decreases cellular contractility on 10 kPa substrates (Figure 9). Overall 
cell-cell junctions on more compliant substrates (2.5 and 5 kPa) were tighter compared to the 
more destabilized, zipper-like junctions seen on less compliant (10 kPa) substrates (Figure 8A). 
Quantification of junction widths (Figure 10B) demonstrated that increasing matrix stiffness 
slightly widens intercellular junction widths on 5 kPa compared to 2.5 kPa substrates and 
significantly (p < 0.05) widens junction width on 10 kPa substrates. This observation is 
consistent with previous work showing a similar trend 
2
. Our data suggests that simvastatin 
treatment slightly decreases cell-cell junction width on less compliant (2.5 and 5 kPa) substrates. 
In addition, our data demonstrates that simvastatin treatment results in a significant (p < 0.05) 
decrease in intercellular junction width on 10 kPa substrates.   
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Figure 10: Quantification of cell-cell junction width. (A) Fluorescent images of VE-cadherin in 
endothelial cell monolayers on 2.5, 5, and 10 kPa gels with and without 1 µM simvastatin 
treatment. Scale bar, 25µm.  (B) Quantification of cell-cell junctions as a represented as a 
function of substrate stiffness and simvastatin treatment. Data ± SEM. * P < 0.05 (Standard Least 
Squares Regression with Tukey’s HSD post hoc.) N=2 with 100 to 200 lines drawn across cell-
cell junctions at each condition.  
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3.5 Simvastatin Treatment Decreases Substrate Stiffness-Dependent Increased 
Permeability 
It has been shown that cellular contractility and junction width play a key role in regulating 
endothelium permeability 
2,42
. We previously showed that simvastatin decreases both cell 
contractility and cell-cell junction width. As such, we sought to determine if these changes 
translated to a change in endothelium permeability. To calculate the relative permeability of the 
endothelial cell monolayers, a solution of FITC-dextran was added to confluent monolayers and 
then imaged to obtain a z-slice (Figure 11B). These images were analyzed to compare the pixel 
intensities above and within the gel resulting in the relative permeability. Two sets of 
permeability experiments were conducted to compare the effect of a longer treatment time with a 
lower concentration (1 µM for 24 hours) to a shorter treatment time with a higher concentration 
(200 µM for 6 hours). Quantification of the endothelium permeability (Figure 11C and D) 
demonstrates that permeability significantly increases on 10 kPa substrates compared to 2.5 kPa 
substrates. This observation is consistent with previous work 
2
. In addition, we note a decreasing 
trend for permeability upon simvastatin treatment at two different treatment conditions, 200 µM 
for 6 hours and 1 µM for 24 hours. Likewise, both treatment conditions (1 µM for 24 hours and 
200 µM for 6 hours) resulted in the reduction of the permeability to a comparable value on 10 
kPa substrates. While preliminary, this data suggests that simvastatin may be able to reverse 
substrate stiffness-dependent increased permeability under various treatment conditions.   
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Figure 11: Quantification of endothelium permeability. (A) Schematic depicting dextran ( ) 
accumulation within gels with cell monolayers. (B) Representative confocal cross sections of (A) 
after addition of FITC-dextran for 5 minutes. The dashed white lines represent the top and bottom 
edges of the gel. Permeability values were calculated by dividing the average pixel intensity within 
the gel by the average intensity above the gel. These values were then normalized to the permeability 
values calculated for no-cell gels to give the relative permeability. (C) Quantified endothelium 
permeability for a 6 hour 200 µM simvastatin treatment. N=1 with 4 to 8 gels per condition. (D) 
Quantified endothelium permeability for a 24 hour 1 µM simvastatin treatment. N=1 with 4 to 8 gels 
per condition. Data collected in collaboration with John Huynh, Ph.D. Data ± SEM. * P < 0.01 
(Standard Least Squares Regression with Tukey’s HSD post hoc). 
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3.6 Simvastatin Treatment Decreases Thrombin Induced Increased Permeability 
Like substrate stiffness, thrombin has been shown to modulate endothelium permeability 
69
 and 
play a key role in the progression of atherosclerosis 
34
. Previous studies have shown that 
simvastatin can reduce increased permeability caused by the transient activation of RhoA leading 
to altered cytoskeletal arrangement upon the addition of thrombin 
32
. As such, we sought to 
investigate the effect of a 6 hour simvastatin pretreatment on attenuating the effect of thrombin 
on endothelium permeability. The concentrations (10, 20, and 50 µM) and time were chosen 
based on previously published data that investigated the ability of simvastatin to attenuate the 
increased permeability observed with thrombin treatment 
50,70–72
 Relative permeability values 
were calculated using the method as previously described (Figure 10A and B). The relative 
permeability of the monolayers (Figure 12) remained relatively consistent, approximately 0.48, 
at each simvastatin concentration for samples that did not receive thrombin after simvastatin 
pretreatment. Quantification of the endothelium permeability for 0, 10, and 20 µM simvastatin 
pretreatments demonstrate that permeability significantly (P < 0.05) increases with thrombin 
treatment. After a 50 µM simvastatin pre-treatment for 6 hours, thrombin no longer caused a 
significant increase in monolayer permeability. This data suggests that 50 µM simvastatin for 6 
hours attenuates thrombin induced increased permeability.  
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Figure 12: Quantification of endothelium permeability on 5 kPa PA gels with and without a 6 
hour simvastatin pre-treatment prior to 10 minute treatment with 4 U/ml thrombin. Data ± SEM. 
N=2 with 8 to 12 gels per condition. * P < 0.05 and NS=not significant (Least Squares Linear 
Regression with Tukey’s HSD post hoc test). 
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CHAPTER 4 
DISCUSSION 
 
One of the initial steps in the progression of atherosclerosis is endothelial cell 
dysfunction, resulting in increased endothelium permeability. This increased endothelium 
permeability ultimately leads to the accumulation of lipids and the formation of an 
atherosclerotic plaque. Traditionally, atherosclerosis is treated using statin therapy to reduce 
blood cholesterol levels. Interestingly, many studies have shown that the off-target effects of 
statins, such as simvastatin, may include the prevention of endothelial cell dysfunction and 
regulation of endothelium permeability. However, these studies were conducted on glass or 
plastic substrates with stiffness significantly higher than those found in the body, and it has 
recently been shown that increasing substrate stiffness has a significant effect on endothelial cell 
function resulting in increased cell contractility and endothelium permeability 
2
. This increased 
contractility and permeability have been shown to be modulated by inhibiting ROCK, a key 
protein in the actomyosin contractility pathway downstream of RhoA, with Y-27632 
2
. As such, 
this study investigated the effect of simvastatin, which has been shown to inhibit RhoA, on 
endothelial cells in an in vitro atherosclerosis model that includes PA substrates with 
physiologically relevant stiffness. This work shows that simvastatin reduces endothelial cell 
contractility, enhances cell-cell junction integrity, and decreases substrate-stiffness dependent 
and thrombin-dependent increased endothelium permeability.  
Simvastatin concentrations and treatment times for our in vitro atherosclerosis model 
were initially established by assessing cell viability and morphology. Cell viability results 
suggest that simvastatin concentrations up to 1 µM for 24 hours show no significant cell death 
compared to control and that concentrations up to 10 µM for 24 hours show minimal cell death. 
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In addition, the results presented show that simvastatin induces a more elongated morphology in 
endothelial cells treated for more than six hours. This finding is consistent with previous work 
showing that monolayers of endothelial cells treated with simvastatin have a more elongated 
morphology compared to untreated monolayers 
52
. This work done with monolayers suggests 
that the morphology results obtained here for isolated cells may translate to monolayers. The 
time scale required to see this morphology change was also consistent with previously published 
work that suggests a simvastatin treatment of at least six hours is required to attenuate increased 
permeability caused by thrombin 
50,51
. This longer time frame may be the result of a lag between 
the effects of simvastatin on Rho family proteins and translation to measurable changes in the 
actin cytoskeleton.  
In this work, we showed that simvastatin reduces endothelial cell contractility, enhances 
cell-cell junction integrity, and decreases substrate stiffness-dependent permeability, all of which 
have implications in the initial stages in the progression of atherosclerosis. Simvastatin has been 
shown to inhibit the geranylgeranylation of RhoA leading to a decrease in membrane bound 
active RhoA which is important in the activation of ROCK and regulation of cell contractility. 
The decreases observed in this work for cellular contractility, cell-cell junction width, and 
endothelium permeability upon simvastatin treatment were not as pronounced as those reported 
after treatment with Y-27632 
2
. This could be explained by the fact that Y-27632 acts further 
downstream in the actomyosin contractility pathway, inhibiting ROCK, when compared to 
simvastatin, which inhibits the geranylgeranylation of RhoA. While ROCK is primarily activated 
by membrane bound active RhoA, a fraction is activated by cytosolic active RhoA which 
suggests that simvastatin treatment only partially inhibits ROCK in the actomyosin contractility 
pathway, while Y-27632 was used at a concentration to completely inhibit ROCK. Further work 
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needs to be conducted to gain a better understanding of the magnitude in which simvastatin is 
downregulating active RhoA, the activation of ROCK, and ultimately the phosphorylation of 
MLC.  
Thrombin has been shown to induce an atherosclerotic phenotype leading to increased 
endothelium permeability through the activation of RhoA and play a role in the progression of 
the later stages of atherosclerosis
32,33
. Our data suggests that pre-incubation with simvastatin 
ameliorates thrombin-enhanced endothelial cell monolayer permeability in a dose-dependent 
manner. These results are consistent with results found in the literature, in which a simvastatin 
pre-treatment prevents thrombin-enhanced endothelium permeability on glass and tissue culture 
plastic substrates 
50,51
. It has been suggested that simvastatin prevents this increased permeability 
through the down regulation of key proteins in the actomyosin contractility pathway such as 
RhoA and MLC-pp 
50–52,56
. This mechanism is analogous to the mechanism by which we 
speculate simvastatin to decrease increased permeability with increasing substrate stiffness, as 
both thrombin and substrate stiffness activate RhoA. Further work needs to be conducted to 
explore the mechanism by which simvastatin ameliorates the dual effects of thrombin and 
increasing substrate stiffness on endothelium permeability. 
The ability of simvastatin to enhance endothelium integrity on substrates with 
physiologically relevant stiffnesses suggests simvastatin as a potential treatment to prevent 
endothelial cell dysfunction and in turn the first step in the progression of atherosclerosis. The 
ability of simvastatin to further attenuate increased endothelium permeability caused by 
thrombin speaks to its ability to prevent endothelial cell dysfunction caused by thrombin which 
occurs during both the early and later stages of atherosclerosis. While further studies need to be 
conducted to understand the exact mechanism by which simvastatin induces these changes and 
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the effect of simvastatin on endothelial cells in a more robust atherosclerosis model that accounts 
for both substrate stiffness and fluid shear stress, these results suggest simvastatin as a potential 
option in the prevention of the initial stages of atherosclerosis.  
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CHAPTER 5 
FUTURE WORK 
 
The data presented in this thesis suggest that simvastatin reduces endothelial cell 
contractility, enhances cell-cell junction integrity, and decreases substrate-stiffness dependent 
and thrombin-dependent increased endothelium permeability. The exact mechanism by which 
simvastatin induces these changes remains unclear.  
Several groups have shown that simvastatin decreases RhoA activity in endothelial cells 
50–52,73
. Given its key role in the actomyosin contractility pathway and previous work suggesting 
that inhibiting RhoA with Y-27632 leads to a decrease in cellular contractility, cell-cell junction 
width, and endothelium permeability 
2
, preliminary experiments were conducted to look at RhoA 
activity as a function of substrate stiffness and 1 µM simvastatin treatment for 24 hours. RhoA 
activity was quantified using a RhoA G-LISA kit (Cytoskeleton). Values of RhoA activity were 
normalized to total DNA values, quantified with a PicoGreen Assay Kit, to account for the 
number of cells on each gel at confluence. RhoA activity was found to slightly increase with 
increasing substrate stiffness for 2.5, 5, and 10 kPa PA substrates (Figure 13). On glass Rho 
activity was much higher than on the PA substrates. While these results are not robust they 
support previous work showing that RhoA activity increases with increasing substrate stiffness 
2
. 
Counter to our expectations, our results suggest that simvastatin does not decrease Rho activity 
on 2.5, 5, and 10 kPa PA substrates. In contrast, our results suggest that simvastatin decreases 
Rho activity on a glass substrate. As this is preliminary work, additional replications of this 
experiment are needed to determine the effect of simvastatin on RhoA activity for cells on 2.5, 5, 
and 10 kPa PA substrates.   
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Figure 13: Effect of simvastatin on RhoA activity in cells plated on substrates of increasing 
stiffness. RhoA activity was quantified using a RhoA G-LISA with or without 1 µM simvastatin 
for 24 hours. RhoA activity was normalized to total DNA quantified using a PicoGreen assay to 
account for the number of cells on confluent samples. Data ± SEM. N=2 with 8 gels per 
condition for 2.5, 5, and 10 kPa PA gels and N=1for glass.  
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These preliminary results raise a number of questions about the mechanism by which 
simvastatin is altering cell morphology and reducing endothelial cell contractility, cell-cell 
junction width, and endothelium permeability on increasing substrate stiffnesses. Additional 
experiments need to be conducted to elucidate the role of RhoA and determine the mechanism by 
which simvastatin is acting on 2.5, 5, and 10 kPa PA substrates to alter cell morphology and 
decrease cell contractility, junction width and ultimately endothelium permeability.  
 As simvastatin is thought to reduce RhoA activity by preventing geranylgeranylation, it is 
possible that while overall levels of active RhoA are staying consistent or slightly increasing, the 
levels of membrane bound active RhoA are actually decreasing. To determine the role of 
cytosolic versus membrane bound active RhoA, separate lysing protocols can be employed to 
distinguish between these two forms of active RhoA. Based on the role of simvastatin, it would 
be expected that simvastatin reduces membrane bound active RhoA.  
 Additionally, it would be beneficial to determine the effect of simvastatin further 
downstream in the actomyosin contractility pathway by quantifying the amount of 
diphosphorylated myosin light chain, MLC-pp, using Western blot. As previously mentioned, 
cell contractility is related to the ratio of MLC-pp to MLC, with endothelial cells becoming more 
contractile as this ratio increases 
22
. Based on this information we would expect to find that 
simvastatin treatment leads to a decrease in MLC-pp. This result has been previously reported in 
the literature under similar simvastatin treatment conditions for endothelial cells grown on glass 
51
.  
Previous studies have suggested that both RhoA and Rac, another protein in the Rho 
GTPase family, act simultaneously to prevent endothelial cell dysfunction and junction 
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destabilization 
50,65,74
. It has been suggested that simvastatin decreases membrane bound Rac by 
inhibiting geranylgeranylation through the isoprenoid biosynthesis pathway previously described 
50,51
. In addition, cytosolic Rac has been shown to increase upon simvastatin treatment, leading to 
stabilization of junctional complexes 
50
. Given its role in stabilizing intercellular junctions and 
the results of previous studies, looking at cytosolic and membrane Rac may help further 
elucidate the mechanism by which simvastatin prevents substrate-stiffness dependent and 
thrombin-dependent increased permeability.  
Additionally, it would be interesting to investigate the effect of simvastatin on endothelial 
cells in a more robust in vitro atherosclerosis model that accounts for both substrate stiffness and 
fluid shear stress. As previously mentioned, substrate stiffness has been shown to affect 
endothelial cell contractility altering endothelium permeability. In addition to being affected by 
the mechanical properties of their matrix, endothelial cell phenotype is also affected by 
mechanical forces due to blood flow. Numerous studies have shown that fluid shear stress plays 
a role in atherosclerosis progression. Areas of low shear stress and disturbed flow patterns are 
more susceptible to plaque formation than areas of high shear stress and laminar flow 
75,76
. A 
limited number of studies have been conducted to examine the effect of simvastatin on 
endothelial cell monolayers exposed to shear stress 
48,77,78
. These studies were conducted with 
cells plated on polystyrene dishes ignoring the fact that in vivo, the intima is much more 
compliant. Because both shear stress
76,79–81
 and matrix stiffness
2,17
 have been shown to 
independently affect cell behavior through integrin-related mechanotransduction pathways and 
the involvement of simvastatin in the actomyosin contractility pathway
42,50,82,83
, it is necessary to 
study these two mechanical stimuli in parallel along with simvastatin treatment to gain a more 
robust idea of the mechanism by which simvastatin modules increased endothelium permeability. 
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Completing the experiments presented above would lead to a better understanding of the 
mechanism by which simvastatin prevents endothelial cell dysfunction. This understanding could 
lead to better treatment and prevention strategies for patients presenting early signs of 
atherosclerosis. 
The work presented in this thesis suggests that simvastatin may have beneficial effects in 
preventing the initial stages of atherosclerosis given its ability to prevent increased endothelium 
permeability caused by thrombin and increased substrate stiffness. It would be interesting to 
investigate the effect of simvastatin on the later stages of atherosclerosis and other aspects of the 
disease such as chemokine involvement and vessel calcification. There are numerous 
chemokines involved in the progression of atherosclerosis and formation of an atherosclerotic 
plaque. Chemokines such as tumor necrosis factor α and platelet-derived growth factor have also 
been shown to have an effect on endothelial cells leading to the activation of Rho family 
proteins
84–86
. The addition of these chemokines to the in vitro atherosclerosis model used in this 
work would allow for the effect of simvastatin on aspects of atherosclerosis beyond mechanical 
stimuli to be further investigated. Vascular calcification is found in most advanced 
atherosclerotic lesions and has been shown to contribute to overall morbidity by decreasing the 
elasticity of blood vessels 
87
. It has been suggested that atherosclerotic calcification is the result 
of induced osteogenic differentiation in subpopulations of vascular cells, such as smooth muscle 
cells, by inflammatory factors 
88
. The calcified plaque has been shown to have a higher stiffness 
than a healthy blood vessel, analogous to the relationship between vessel stiffness of young and 
old arteries 
89
. Given this similarity it would be interesting to investigate the effect that the 
calcified plaque has on endothelial cell function and whether simvastatin is able to attenuate 
increased permeability that may result from the endothelial cells being exposed to a stiffer 
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matrix. Currently the ability of simvastatin to effectively treat the later stages of atherosclerosis 
remains unclear. This work would further our knowledge of simvastatin’s ability to attenuate 
endothelial cell dysfunction and potential to treat the later stages of atherosclerosis. 
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